Concept
Treatment Findings
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / Key Takeaways
"Camizestrant plus a CDK4/6 inhibitor established ctDNA-detected emergent ESR1 mutation as an on-treatment switch trigger, improving PFS versus continuing initial endocrine therapy.\n\nSevabertinib achieved a 75% ORR in previously untreated HER2-mutant advanced nonsquamous NSCLC, reinforcing comprehensive tumor/blood genotyping prior to first-line selection."
Related Ideas
- Etcamah Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Blood Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- Treatment Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Treatment Combination10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Imlunestrant Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References:
- Dynamic CtdnaFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance